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ABSTRACT
Objective: To assess the cost-effectiveness of cardiac
resynchronisation therapy (CRT) both with CRT-P
(biventricular pacemaker only) and with CRT-D
(biventricular pacemaker with deﬁbrillator) in patients
with New York Heart Association (NYHA) functional
class III/IV from a Belgian healthcare-payer
perspective.
Methods: A lifetime Markov model was designed to
calculate the costeutility of both interventions. In the
reference case, the treatment effect was based on the
Comparison of Medical Therapy, Pacing and
Deﬁbrillation in Heart Failure trial. Costs were based on
real-world data. Pharmacoeconomic guidelines were
applied, including probabilistic modelling and
sensitivity analyses.
Results: Compared with optimal medical treatment, on
average 1.31 quality-adjusted life-years (QALY) are
gained with CRT-P at an additional cost of €14700,
resulting in an incremental cost-effectiveness ratio
(ICER) of about €11200/QALY. As compared with
CRT-P, CRT-D treatment adds on average an additional
0.55 QALYs at an extra cost of €30900 resulting in an
ICER of €57000/QALY. This result was very sensitive
to the incremental clinical beneﬁt of the deﬁbrillator
function on top of CRT.
Conclusions: Based on efﬁciency arguments, CRT-P
can be recommended for NYHA class III and IV
patients if there is a willingness to pay more than
€11000/QALY. Even though CRT-D may offer
a survival beneﬁt over CRT-P, the incremental clinical
beneﬁt appears to be too marginal to warrant
a threefold-higher device price for CRT-D. Further
clinical research should focus on the added value of
CRT-D over CRT-P.
INTRODUCTION
Heart failure (HF) is a complex clinical
syndrome that can result from any cardiac
disorder that impairs the ability of the heart
to function as a pump. Patients who are
clinically stable but suffer from a severely
reduced contractile function (left ventricular
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ARTICLE SUMMARY
Article focus
- To assess the cost-effectiveness of cardiac
resynchronisation therapy (CRT) both with
CRT-P (biventricular pacemaker only) and with
CRT-D (biventricular pacemaker with deﬁbril-
lator).
Key messages
- CRT-P can be recommended for reimbursement
for New York Heart Association class III and IV
patients if there is a willingness to pay more than
€11000/quality-adjusted life-year.
- Current evidence is insufﬁcient to show the
superiority of CRT-D over CRT-P. With a three-
fold-higher device cost, CRT-D’s cost-effective-
ness is questionable.
Strengths and limitations
- Hospital billing data of 342 Belgian CRT
implantations were at our disposal for cost
calculations.
- TheresultsoftheComparisonofMedicalTherapy,
Pacing and Deﬁbrillation in Heart Failure trial were
used to model the treatment effect. This happens
tobetheonlytrialthatcomparedCRT-Paswellas
CRT-Dversusoptimalpharmacologicaltreatment,
allowing an indirect comparison to be made
between CRT-P and CRT-D.
- Following health economic theory, CRT-D is
compared with CRT-P, not with optimal pharma-
cological treatment (ie, working on the cost-
efﬁciency frontier).
- A direct estimate of the added value of CRT-D
versus CRT-P in patients with moderate to
severe heart failure is lacking. This may be an
interesting topic for further research in a rando-
mised controlled trial, especially because of the
threefold higher price for a CRT-D device versus
CRT-P.
- Generic utility instruments to measure quality of
life are not always used in clinical trials. To
support economic evaluations, it would be useful
to include more systematically a generic utility
instrument in the study protocol.
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Open Access Researchejection fraction; LVEF#35%) remain at high risk of
sudden cardiac death (SCD).
1 Approximately 50% of
deaths in patients with HF are due to a sudden cardiac
arrest.
2 Therefore, HF patients are potential candidates
for treatment with an implantable cardioverter deﬁbril-
lator (ICD). Selected patients with end-stage HF, who
remain symptomatic despite optimal pharmacological
treatment (OPT), could also be considered for cardiac
resynchronisation therapy (CRT).
3 The scope of this
manuscript is to calculate CRT’s cost-effectiveness in
order to provide reimbursement advice to the Belgian
competent authorities.
CRT can be offered by two types of devices: biven-
tricular pacemakers, also called CRT-P devices, and
biventricular deﬁbrillators, also known as CRT-D devices.
CRT aims to improve the heart’s contractile function by
electrically stimulating the cardiac chambers, thus
synchronising their contraction. A CRT-D device offers
the additional ability to stop life-threatening ventricular
arrhythmias preventing SCD.
The Belgian Health Care Knowledge Centre (KCE), an
independent semigovernmental institution, conducted
a health technology assessment (HTA) about the clinical
effectiveness and cost-effectiveness of CRT for HF
patients.
METHODS
A Markov simulation model was developed in order to
evaluate the cost-effectiveness of CRT-P and CRT-D
therapy. Both cost-effectiveness, expressing results in
additional expenses for a life-year gained (LYG), and
costeutility analyses using quality-adjusted life-years
(QALYs) gained were performed.
The analysis included direct healthcare costs from the
perspective of the healthcare payer. In Belgium this
constitutes payments from the government’s healthcare
budget as well as patients’ co-payments. Dealing with
a chronic disease, a lifetime horizon was also applied.
Future costs and beneﬁts were discounted at a rate of 3%
and 1.5%, respectively, according to national pharma-
coeconomic guidelines.
4 In scenario analyses, these rates
were subsequently changed.
To capture parameter uncertainty, input variables were
modelled as probabilistic values. The choice of distri-
bution depends on the characteristics of the input vari-
ables.
5 Owing to the central limit theorem, parameters
can be sampled from a normal distribution with the
appropriate CI around the mean. The b distributions are
used for parameters constrained to the interval 0e1
(such as quality-of-life (QoL) values). g Distributions are
used for skewed variables. One thousand Latin hyper-
cube simulations were generated in MicroSoft Excel
using the @Risk (Palisade Corporation) add-in program.
The interventions of interest, CRT-P and CRT-D, are
always provided on top of OPT. Hence, OPT is the initial
comparator for both CRT-P and CRT-D to determine
their position on the cost-effectiveness plane (which
presents the difference in effects on the x-axis and
differences in costs on the y-axis). The incremental cost-
effectiveness ratios (ICERs), comparing incremental
costs with incremental effects, were calculated on the
efﬁciency frontier. According to health-economic
theory,
5 ICERs should be calculated on this frontier
comparing an intervention with the previous most cost-
effective intervention. To be able to interpret results,
cost-effectiveness acceptability curves are presented,
expressing the probability that an intervention is
considered cost-effective (y-axis) depending on the will-
ingness to pay (WTP) for an additional QALY (x-axis).
Model
The model simulated a hypothetical cohort of 1000 CRT-
eligible patients. The type of participants considered
were patients with moderate-to-severe heart failure
(NYHA class IIIeIV) with low ejection fraction (#35%)
and delayed intraventricular conduction evidenced by
a wide QRS complex. In the base case scenario, the
patient population was 67 years old, and 67.4% were
male, corresponding to the patients who were enrolled
in the Comparison of Medical Therapy, Pacing and
Deﬁbrillation in Heart Failure (COMPANION) trial.
6
Baseline employment rates can safely assumed to be low
in this population, and therefore indirect productivity
costs were ignored.
In the literature review on effectiveness of CRT,
7 all-
cause mortality and hospitalisation owing to heart failure
were considered as primary endpoints. This was
reﬂected in the Markov model with monthly cycles
(ﬁgure 1). Patients receiving a CRT-P/D were subject to
a procedure-related mortality risk. Furthermore, every
month, patients were at risk of all-cause death. Survivors
receiving OPT during that month were at risk of hospi-
talisation owing to heart failure and could receive an
upgrade (either from OPT to ICD or from CRT-P to
CRT-D).
Mortality
Randomised trials have shown that both CRT-P and
CRT-D, in addition to OPT, prolong life in subsets of
patients with NYHA class III/IV heart failure.
6 8 The
results of the COMPANION trial
6 were used to model
the treatment effect. This was the only trial that
compared CRT-P+OPT as well as CRT-D+OPT versus
OPT, allowing an indirect comparison to be made
between CRT-P and CRT-D. Based on this trial, the
monthly probability of death was 0.017 for the OPT
group.
9 Applying the reduced mortality risk of 24%
(p¼0.059) and 36% (p¼0.003) for CRT-P and CRT-D
resulted in a monthly probability of 0.013 and 0.011,
respectively. A normal distribution was used to account
for the uncertainty around these numbers.
In the COMPANION trial, the median follow-up time
was 14.8 months, 16.5 months and 16.0 months, for the
OPT, CRT-P and CRT-D group, respectively.
6 In our
model, extrapolation started after month 16 for the
three intervention groups. The monthly probability of
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Cost-effectiveness of cardiac resynchronisation therapydeath was made time-dependent by adding the absolute
monthly increase in mortality of the normal age- and
gender-adjusted Belgian population.
In a systematic review of clinical trials on CRT,
10 21
perioperative deaths were counted among 2757 patients
(table 1). This procedure-related mortality risk of both
CRT-P and CRT-D implantations was accounted for by
applying a b-distribution. However, in order to avoid
double counting, monthly mortalities during the ﬁrst
year were slightly adjusted downwards, keeping the
original trial-based 1-year mortality at the same level.
Hospitalisations
Hospitalisation rates were based on the COMPANION
trial as reported by Feldman et al.
9 The monthly proba-
bility of hospital admission was estimated to be 0.117 for
the OPT group, 0.098 (p¼0.172) for CRT-P and 0.097
(p¼0.141) for the CRT-D group (table 1). The uncer-
tainty around these numbers was accounted for with
a normal distribution. In our reference case, the hospi-
talisation rates were assumed to be constant over the full
time horizon. This was subsequently altered during
a scenario analysis.
Costs
An average cost of €23380 (95% CI of the mean 22842
to 23919) for a primo CRT-D implantation was obtained
from the actual hospital billing data of 342 Belgian
CRT-D primo implantations that occurred during the
period 2008 until mid 2009. This cost was modelled with
a normal distribution (table 1). The implantation cost of
a primo CRT-P was inferred by subtracting the cost
difference from the CRT-D implantation cost. Based on
the reimbursement tariffs, the price for CRT-P and
CRT-D, including leads, was €7187 and €21170, respec-
tively.
7 As such, the average cost for CRT-P implantation
was €9398 (95% CI of the mean €8859 to 9936).
A similar approach was used for the cost of a device
replacement. Based on Belgian data (n¼121), the CRT-D
replacement cost was €21905 (95% CI of the mean
€21111 to €22700). With a price difference between the
CRT-P and CRT-D device of €12844, this amounted to
€9061 (95% CI of the mean €8267 to €9856) for CRT-P.
Service life was equal to the average of expert opinion-
based service lives encountered in other studies,
9 10 that
is 75 months for CRT-P and 60 months for CRT-D. This
assumption was altered in various scenario analyses.
Data from the Belgian Technical Cell (http://www.tct.
fgov.be) served as the source for obtaining hospital-
isation costs. The cost for ‘APR-DRG 194 Heart Failure’
was on average €5529 (90% CI 1233 to 14132) per
hospitalisation based on data from more than 19000
hospitalisation episodes in the year 2007. This cost was
included as a g distribution and adjusted to 2008 values
(Consumer Price Index of 104.5% or on average €5777)
(table 1).
Figure 1 Decision model for
cardiac resynchronisation therapy
(CRT) with biventricular
pacemaker only (CRT-P) and CRT
with biventricular pacemaker with
deﬁbrillator (CRT-D). ICD,
implantable cardioverter
deﬁbrillator; OPT, optimal
pharmacological treatment;
proc.-rel., procedure-related.
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Cost-effectiveness of cardiac resynchronisation therapyPrescription medication use was taken from the avail-
able data on the Belgian CRT population, right before
implantation.
7 The amount and type of drugs were
assumed to remain the same after implantation on a per
patient base. Prescription medication costs were based
on the cheapest formulation as indicated by the Belgian
Centre for Pharmacotherapeutic Information (http://
www.bcﬁ.be accessed November 2010). The percentage
Table 1 Input variables for the Markov model
Range
(95% CI)*
Mean 2.5% 97.5% Distribution Source
Characteristics of the population
Start age of the cohort 67
years
/ / / COMPANION trial
6
Proportion male 67% / / /
Mortality (monthly)
OPT 0.017 / / / Feldman et al
9
CRT-P 0.01292 0.00868 0.01716 Normal Feldman et al
9; COMPANION
trial
6 and own calculations CRT-D 0.01088 0.00801 0.01375 Normal
Procedure related mortality
ab
Perioperative deaths 0.76% 21 2736 b Fox et al
10
Hospitalisations (monthly probability of hospital admission)
OPT 0.117 / / / Feldman et al
9
CRT-P 0.098 0.0707 0.1253 Normal Feldman et al
9 and
own calculations CRT-D 0.097 0.0704 0.1236 Normal
Length of stay
Primo implantation 7.34 6.2 8.48 Normal Belgian database
Replacement 4.47 3.53 5.41 Normal
Utility weights
OPT 0.68 0.63 0.73 b Cleland et al
8; Calvert et al
11;
Feldman et al
9 and own
assumptions
CRT-P 0.78 0.73 0.83 b
CRT-D 0.78 0.73 0.83 b
Hospitalisation primo implantation
or replacement
0.46 0.41 0.51 b
Costsy
Primo implantation
CRT-P €9398 €8859 €9936 Normal Belgian database, reimbursement
tariffs and own adaptions CRT-D €23380 €22842 €23919 Normal
ICD €27261 €26867 €27658 g Belgian Health Care Knowledge
Centre report implantable
cardioverter
deﬁbrillators
12
Replacement
CRT-P €9061 €8267 €9856 Normal Belgian database, reimbursement
tariffs and own adaptions CRT-D €21905 €21111 €22700 Normal
Hospitalisation €5777 €1129 €17807 g Technical Cell (All Patient Reﬁned
Diagnosis Related Groups 194 ‘heart
failure’)
Follow-up medication
(monthly cost)
€30.88 €29.85 €31.82 b for
volumes
Belgian database (volumes) and
Belgian Centre for Pharmacotherapeutic
Information (prices)
Follow-up visits (average
monthly cost)
OPT CRT-P CRT-D
GP, cardiologist (ECG, echo,
integrity check)
€52.98 €71.87 €90.77 b for
volumes
Expert opinion
Crossover/upgrade
OPTdICD 0.0015  50% +50% Uniform Bond et al
13
CRT-PeCRT-D 0.0005  50% +50% Uniform
*95% CI, unless otherwise mentioned.
yUnless otherwise stated in the text, the year of costs reﬂects 2008 values.
/, ﬁxed value in the model; COMPANION, Comparison of Medical Therapy, Pacing and Deﬁbrillation in Heart Failure; CRT-P/D, cardiac
resynchronisation therapy (CRT) both with pacemaker (CRT-P) and additionally including a deﬁbrillator (CRT-D); ECG, electrocardiogram;
GP, general practitioner; ICD, implantable cardioverter deﬁbrillator; OPT, optimal pharmacological treatment.
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Cost-effectiveness of cardiac resynchronisation therapyof users was included as a b distribution with parameters
reﬂecting the values of the Belgian CRT sample. The
average monthly medication cost was €30.88 per patient
(95% CI 29.85 to 31.82) (table 1). Details are presented
as a data supplement (www.jamia.org).
Based on expert opinion, we assumed that patients
consulted their cardiologist four times a year at €34.02
per consultation, and received GP visits at €19.37 per
visit for the remaining 8 months of the year. This was
modelled applying a b distribution with the minimum
and maximum 650% above/under the average. For
every consultation an ECG (€16.94) and echocardio-
graphic examination (€69.24) were billed as well. A CRT
integrity check was also counted at €56.68 for CRT-P and
€113.36 for CRT-D systems. As such, the monthly visit
costs for OPT, CRT-P and CRT-D were respectively
€52.98, €71.87 and €90.77 (table 1).
Finally, the model also included a possibility for
crossover or upgrade. Patients in the OPT group could
receive an ICD, whereas patients in the CRT-P group
could be upgraded to CRT-D. Medical therapy and CRT
recipients received an ICD in the model of Bond et al
13/
Fox et al
10 as soon as they survived a serious arrhythmic
event. Based on their model, we included upgrade
probabilities of 0.0015 and 0.0005 per month for the
OPT and CRT-P group, respectively (table 1). These
probabilities were multiplied with a uniform distribution
(0.5e1.5) to reﬂect the large uncertainty around these
numbers. The cost of an ICD implantation was based on
another Belgian ICD study and amounts to €27261
(95% CI 26867 to 27658).
12 We preferred not to index
this cost, since the reimbursement price for the device
has decreased since then. For an upgrade from CRT-P to
CRT-D, the cost of a CRT-D replacement was taken into
account. Crossover- or upgrade-related procedural
deaths were not explicitly accounted for, since we
assumed these to be reﬂected in the initial intention-to-
treat mortalities.
Utilities
Utility values were based on the studies of Cleland et al,
8
Calvert et al
11 and Feldman et al
9 The baseline out-of-
hospital utility was set to 0.68 (table 1).
9 The utility
improvement in the CRT-P/D groups was estimated to
amount to 0.1,
891 1resulting in a utility weight of 0.78. An
average utility weight of 0.46 was incorporated during the
hospital stay of the initial and replacement implanta-
tions, which averaged 7.34 days and 4.47 days respectively
in the Belgian CRTsample (table 1). Details of the studies
that support these utility values are brieﬂy outlined in
the data supplement on utilities (www.jamia.org).
Sensitivity and scenario analyses
Results of the probabilistic model are presented on the
cost-effectiveness plane and as cost-effectiveness accept-
ability curves. Several scenario analyses are performed
for mortalities, hospitalisations, discount rates and
device service life.
RESULTS
According to the model, the undiscounted life expec-
tancy is 4.6 years for the OPT group. CRT-P increases life
expectancy with 1.31 years (95% CI  0.04 to 3.21).
CRT-D adds another 0.8 years (95% CI  1.40 to 2.95) on
top of CRT-P. If QoL changes are taken into account, this
becomes 1.47 QALYs (95% CI 0.39 to 3.00) and 0.63
QALYs (95% CI  1.18 to 2.38), respectively. This results
in a discounted incremental effect adjusted for quality of
life of 1.31 QALYs (95% CI 0.36 to 2.64) and 0.55 QALYs
(95% CI  1.02 to 2.07), respectively.
The average incremental cost is <€15000 for CRT-P
versus OPT. In combination with the discounted gain in
life expectancy, this results in an average ICER of about
€12800/LYG. If QoL adjustments are taken into
account, this becomes €11200/QALY gained. The ICER
of CRT-D versus OPT is higher than that of CRT-P versus
OPT; thus calculating the ICER on the efﬁciency fron-
tier, CRT-P becomes its economic justiﬁed comparator.
The total incremental cost of CRT-D versus CRT-P is on
average more than €30000. The ICER becomes on
average €44100/LYG or €56600/QALY gained. More
details and CIs are available in the data supplements
(www.jamia.org).
Figure 2 shows the cost-effectiveness plane; on top
both CRT-P and CRT-D versus OPT (incremental effects
on the x-axis expressed as QALYs gained), while at the
bottom CRT-P becomes the comparator for CRT-D. The
scatter plot clearly shows the impact of considering CRT-P
as the comparator for CRT-D. If we compare CRT-D with
OPT, then the simulations are completely in the ﬁrst
quadrant. In contrast, if we compare CRT-D with CRT-P,
about 23% of the simulations are situated in the domi-
nated quadrant (being more costly and less effective).
For each of the 1000 simulations, ICERs are calculated,
allowing the results to be expressed as the probability
that the three alternatives are considered cost-effective
depending on the WTP for a QALY. Figure 3 shows these
cost-effectiveness acceptability (CEA) curves. OPT is the
preferred option if the WTP for a QALY gained is
<€11000. Above this threshold, CRT-P is most probably
the best alternative with a probability of about 90% at
a threshold of about €21000 per QALY gained. If this
willingness is more than €30000, the probability that
OPT is chosen is almost nil. This WTP has to increase to
more than €56000 per QALY gained for CRT-D to have
a probability of more than 50% for being considered
a cost-effective alternative. The fact that there is still
a probability that CRT-P is cost-effective at this high WTP
threshold illustrates the uncertainty around the incre-
mental beneﬁt of CRT-D versus CRT-P.
Scenario analyses on mortality, hospitalisation and
discount rates revealed that the results for CRT-P versus
OPT can be considered robust. The difference in cost-
effectiveness between CRT-P and CRT-D is mainly
determined by the threefold-higher device price for
a CRT-D versus CRT-P. Furthermore, at current price
differences between CRT-P and CRT-D, small
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Cost-effectiveness of cardiac resynchronisation therapyincremental beneﬁts of CRT-D versus CRT-P result in
relatively unfavourable cost-effectiveness ratios for CRT-
D. For the results of these scenario analyses, we refer to
the data supplements and the full HTA report (www.
jamia.org).
7
DISCUSSION
In previously published health economic evaluations of
CRT, ICERs vary considerably, both for CRT-P versus
OPT (from €3600
14 to $108000
15 per QALY gained) and
for CRT-D versus CRT-P (from £40200
13 to $172300
9 per
QALY gained). A detailed overview of these evaluations
is available in the full HTA report.
7 Since costs and
resource use may widely vary across countries and
because of methodological considerations, results might
not be applicable to Belgian practice, and thus it was
decided to perform a health-economic evaluation of
CRT from a Belgian healthcare-payer perspective.
Compared with OPT, on average 1.31 QALYs are
gained with CRT-P at an additional cost of €14700,
resulting in a relatively robust ICER of about €11200/
QALY. Reimbursing CRT-P can thus be considered as
efﬁcient use of limited sources if the WTP is higher than
€11000 for a QALY gained. Compared with CRT-P, CRT-
D provides on average 0.55 QALYs at an extra cost of
€30900 or an average ICER of €57000/QALY. This
result largely depends on the added value of CRT-D
versus CRT-P. Based on our indirect comparison, CRT-D
was dominated by CRT-P in about 23% of the simula-
tions. Current evidence is insufﬁcient to show the
superiority of CRT-D over CRT-P. With a threefold-higher
device cost, CRT-D’s cost-effectiveness is questionable.
All economic evaluations, including our own model,
are subject to a number of common limitations. First,
there is the short-term follow-up of the trials necessi-
tating extrapolation assumptions. Second, the economic
evaluations are limited by the external validity of the trial
results. The technical skills of providers, patient selec-
tion and differences in the optimal treatment regimen
may vary in real-world practice and affect the clinical
effectiveness of the therapy. For example, only experi-
enced providers participated in the trials. Therefore, it is
possible that the complication rates are not general-
isable to other, less experienced, provider settings, and
results of the economic models may be biased in favour
of CRT.
Furthermore, economic evaluations are limited by the
way in which QoL was included. Generic utility instru-
ments to measure QoL are not systematically used in
trials. In contrast to this economic evaluation, several
studies include utility values by NYHA class rather than
for the different treatment groups. The validity of this
Figure 3 Cost-effectiveness acceptability curves for the three
alternative treatment options: optimal pharmacological
treatment (OPT), cardiac resynchronisation therapy with
biventricular pacemaker only (CRT-P) and cardiac
resynchronisation therapy with biventricular pacemaker with
deﬁbrillator (CRT-D). QALY, quality-adjusted life-year.
Figure 2 Cost-effectiveness planes for cardiac
resynchronisation therapy with biventricular pacemaker only
(CRT-P)/cardiac resynchronisation therapy with biventricular
pacemaker with deﬁbrillator (CRT-D) versus optimal
pharmacological treatment (top) and CRT-D versus CRT-P
(bottom). QALYs, quality-adjusted life-years.
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Cost-effectiveness of cardiac resynchronisation therapyapproach depends on a double link: ﬁrst, the link
between the treatment and the outcome (in terms of
NYHA class, which is a subjective measure for functional
disability); second, the link between NYHA class and
QoL. Such indirect determination bears an increased
risk of inaccuracy. Since NYHA class utility estimates vary
substantially between publications,
7 and results can be
somewhat manipulated. It would be useful to include
more systematically a generic utility instrument to
measure QoL in trials. Calvert et al
11 showed that the
EQ-5D appears to be an acceptable valid measure for use
in patients with HF. Nevertheless, a minority of studies
include such an instrument in addition to disease-
speciﬁc instruments in their research protocol.
In our assessment of the costeutility of CRT, we
found that, compared with OPT, CRT-P has a better cost-
effectiveness ratio than CRT-D. Therefore, the relevant
comparator for assessing the cost-effectiveness of CRT-D,
which is marginally and non-signiﬁcantly more efﬁca-
cious regarding mortality than CRT-P, is therefore CRT-P.
The chosen comparator obviously may have a large
impact on the resulting ICER. Feldman et al,
9 for
instance, compared both CRT-P and CRT-D with OPT,
but did not compare CRT-D with CRT-P. The ICER of
CRT-D compared with OPT as reported by Feldman et al
was $43000 per QALY, whereas the ICER compared with
CRT-P would have resulted in $172300 per QALY.
Economic evaluations should be performed on the
so-called ‘efﬁciency frontier,’ and choosing an inappro-
priate comparator may inﬂuence results in a misleading
way and alter conclusions.
A direct comparison of the performance of CRT-P
versus CRT-D has not yet been performed. A Bayesian
network meta-analysis of randomised controlled trials
indicated that evidence is insufﬁcient to show the supe-
riority of CRT-D over CRT-P in these patients.
16 The
added value of CRT-D versus CRT-P in patients with
moderate to severe HF is unknown and may be an
interesting topic for further research in a randomised
controlled trial, especially because of the threefold-
higher price for a CRT-D device versus CRT-P.
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